MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-18-2366

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2018

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.

Hurvitz Sara A, O'Shaughnessy Joyce, Mason Ginny, Yardley Denise A, Jahanzeb Mohammad, Brufsky Adam, Rugo Hope S, Swain Sandra M, Kaufman Peter A, Tripathy Debu, Chu Laura, Li Haocheng, Antao Vincent, Cobleigh Melody

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Patients with HER2-positive metastatic breast cancer (MBC) with central nervous system (CNS) metastasis have a poor prognosis. We report treatments and outcomes in patients with HER2-positive MBC and CNS metastasis from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs).

EXPERIMENTAL

DESIGN

SystHERs (NCT01615068) was a prospective, U.S.-based, observational registry of patients with newly diagnosed HER2-positive MBC. Study endpoints included treatment patterns, clinical outcomes, and patient-reported outcomes (PRO).

RESULTS

Among 977 eligible patients enrolled (2012-2016), CNS metastasis was observed in 87 (8.9%) at initial MBC diagnosis and 212 (21.7%) after diagnosis, and was not observed in 678 (69.4%) patients. White and younger patients, and those with recurrent MBC and hormone receptor-negative disease, had higher risk of CNS metastasis. Patients with CNS metastasis at diagnosis received first-line lapatinib more commonly (23.0% vs. 2.5%), and trastuzumab less commonly (70.1% vs. 92.8%), than patients without CNS metastasis at diagnosis. Risk of death was higher with CNS metastasis observed at or after diagnosis [median overall survival (OS) 30.2 and 38.3 months from MBC diagnosis, respectively] versus no CNS metastasis [median OS not estimable: HR 2.86; 95% confidence interval (CI), 2.05-4.00 and HR 1.94; 95% CI, 1.52-2.49]. Patients with versus without CNS metastasis at diagnosis had lower quality of life at enrollment.

CONCLUSIONS

Despite advances in HER2-targeted treatments, patients with CNS metastasis continue to have a poor prognosis and impaired quality of life. Observation of CNS metastasis appears to influence HER2-targeted treatment choice.

Для цитирования: Hurvitz Sara A, O'Shaughnessy Joyce, Mason Ginny, Yardley Denise A, Jahanzeb Mohammad, Brufsky Adam, Rugo Hope S, Swain Sandra M, Kaufman Peter A, Tripathy Debu, Chu Laura, Li Haocheng, Antao Vincent, Cobleigh Melody. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. DOI: 10.1158/1078-0432.ccr-18-2366.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.